Literature DB >> 21831160

Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates.

S Chen Song1, S Zhong, Y Xiang, J-H Li, H Guo, W-Y Wang, Y-L Xiong, X-C Li, S Chen Shi, X-P Chen, G Chen.   

Abstract

Protection against humoral injury mediated by donor-specific antibodies (DSA), also known as accommodation, may allow for long-term allograft survival in presensitized recipients. In the present study, we determined the role of complement in renal allograft accommodation in donor skin-presensitized nonhuman primates under conventional immunosuppression. Donor skin allografts were transplanted to presensitized recipients 14 days prior to renal transplantation. Renal allografts not receiving any immunosuppressive treatment developed accelerated rejection with predominantly humoral injury, which was not prevented using conventional cyclosporine (CsA) triple therapy. Inhibition of complement activation with the Yunnan-cobra venom factor (Y-CVF) successfully prevented accelerated antibody-mediated rejection and resulted in successful accommodation and long-term renal allograft survival in most presensitized recipients. Accommodation in this model was associated with the prevention of the early antibody responses induced against donor antigens by complement inhibition. Some antiapoptotic proteins and complement regulatory proteins, including Bcl-2, CD59, CD46 and clusterin, were upregulated in the surviving renal allografts. These results suggest that the complement inhibition-based strategy may be valuable alternative in future clinical cross-match positive or ABO-incompatible transplantation. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21831160     DOI: 10.1111/j.1600-6143.2011.03646.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  28 in total

Review 1.  From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; George Hajishengallis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2016-06-16       Impact factor: 3.144

Review 2.  The role of complement in antibody-mediated rejection in kidney transplantation.

Authors:  Mark D Stegall; Marcio F Chedid; Lynn D Cornell
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

Review 3.  New milestones ahead in complement-targeted therapy.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-06-16       Impact factor: 11.130

Review 4.  Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment.

Authors:  Maurizio Salvadori; Giuseppina Rosso; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2015-06-24

Review 5.  Strategies to overcome the ABO barrier in kidney transplantation.

Authors:  Georg A Böhmig; Andreas M Farkas; Farsad Eskandary; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2015-09-01       Impact factor: 28.314

6.  Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management.

Authors:  Carrie Schinstock; Mark D Stegall
Journal:  Curr Transplant Rep       Date:  2014-03-13

7.  Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Methods Mol Biol       Date:  2013

Review 8.  The Complement System and Antibody-Mediated Transplant Rejection.

Authors:  Erik Stites; Moglie Le Quintrec; Joshua M Thurman
Journal:  J Immunol       Date:  2015-12-15       Impact factor: 5.422

Review 9.  Complement in immune and inflammatory disorders: therapeutic interventions.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 10.  Complement in immune and inflammatory disorders: pathophysiological mechanisms.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.